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Alzheimer’s disease (AD) is characterised by the aggregation of two quite diﬀerent proteins, namely, amyloid-beta (Aβ), which
formsextracellularplaques,andtau,themaincomponentofcytoplasmicneuroﬁbrillarytangles.Theamyloidhypothesisproposes
thatAβplaquesprecedetangleformationbutthereisstillmuchcontroversyconcerningtheorderofeventsandthelinkagebetween
Aβ and tau alterations is still unknown. Mathematical modelling has become an essential tool for generating and evaluating
hypotheses involving complex systems. We have therefore used this approach to discover the most probable pathway linking Aβ
andtau.ThemodelsupportsacomplexpathwaylinkingAβ andtauviaGSK3β,p53,andoxidativestress.Importantly,thepathway
contains a cycle with multiple points of entry. It is this property of the pathway which enables the model to be consistent with both
the amyloid hypothesis for familial AD and a more complex pathway for sporadic forms.
1.Introduction
Alzheimer’s disease (AD) is characterised by the presence
of extracellular amyloid-beta (Aβ) plaques and cytoplasmic
tau tangles and the loss of neurons in speciﬁc regions of
the brain. The connection between these events is still not
clear although it has been proposed that the formation of
plaques precedes the appearance of tangles which in turn
precedes cell death [1, 2]. Confounding the acceptance of
such a simple temporal order of events is evidence that
plaques are not necessary for disease progression [3]a n d
that the accumulation of plaques can also occur as part of
normal ageing with no apparent pathology [4]. Moreover,
soluble Aβ may be a better correlate of disease than the
insoluble plaques [5, 6]. It has recently been suggested that
the amyloid hypothesis may only hold for familial forms of
the disease but that the situation is much more complex in
late-onset forms [7]. It is also possible that Aβ is a damage
response protein [8]. Small and Duﬀ [7]suggest that the
pathway between Aβ and tau is linear for early-onset AD
but hypothesize that a dual pathway links the two in late-
onset disease [7]. A number of molecular pathways have
been proposed as the upstream driver of both Aβ and tau
aggregates. One important candidate is glycogen synthase
kinase-3β (GSK3β). It is well established that GSK3β activity
leads to hyperphosphorylation of tau and there is also
evidence that it accounts for increased production of Aβ [9].
ItsimportanceinADwashighlightedin2008bytheproposal
of a “GSK3 hypothesis of AD” [10] .Ar e c e n tr e v i e wa l s o
surveys data in support of the contention that GSK3β
provides the link between Aβ and tau [11]. In addition it has
been shown that Aβ behaves like an antagonist of insulin
and prevents activation of Akt [12]. Akt phosphorylates
GSK3β which inhibits its activity; Aβ therefore indirectly
increases the activity of GSK3β. There is also a link between
p53 and GSK3β and we recently modelled this to show
that this interaction might explain the link between protein
aggregation and neuronal loss in AD [13]. The model
predicts that GSK3β overactivity leads to an increase in levels
of Aβ plaques and tau tangles by independent processes
supporting the idea of a dual pathway.
One way to examine the order of events in disease
pathology is to prevent the formation of plaques and then
observe whether or not tau tangles appear. An experimental2 International Journal of Alzheimer’s Disease
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Figure 1: Alternative hypotheses for the link between Aβ and tau. (a) Linear pathway. (b) Dual pathway. (c) Complex pathway.
p r o c e d u r ef o rd o i n gt h i si sA β immunization which has been
carried out in many mouse models and also in a number
of human clinical trials. Many of the mouse models do not
have tau pathology and so cannot be used to test hypotheses
concerning the order of events. In the more relevant 3×Tg-
AD mouse model, experiments indicated that reducing
plaques also led to the clearance of early tau pathology [14].
On the other hand human clinical trials have not shown
any clear evidence of a reduction in tau tangles in regions
where plaques were reduced [15]. Our model of GSK3/p53
[13] can examine the eﬀect of increased clearance of Aβ by
the simple modiﬁcation of increasing the rate of Aβ (soluble
form)removal.Bydoingsoitispossibletotestwhetherthere
is a linear or a dual pathway. If the pathway is linear, then the
modelshouldpredictthatincreasingclearanceofAβwillalso
reduce the formation of tau tangles (Figure 1(a)). If there is
a dual pathway, then increasing the clearance of Aβ will not
aﬀect the levels of tau tangles (Figure 1(b)). However, there
is a third possibility (complex pathway): Aβ may not directly
aﬀect the formation of tau tangles in a linear pathway but
may still have indirect eﬀects (Figure 1(c)).
2. Methods
We previously built a stochastic dynamic model of p53 reg-
ulation [16] which was then extended to include GSK3β,A β
and tau [13]. The models are encoded in the Systems Biology
Markup Language (SBML), a computer-readable format for
network models [17]. SBML allows models to be easily
modiﬁed and extended and also enables sharing of models
since the code is publicly available from the Biomodels
database [18]. The extended GSK3 model includes a module
for the DNA damage response which leads to elevated levels
of p53, which can then bind to GSK3β. We assume that
binding of GSK3β to p53 increased the activity of both
proteins. The model includes a module for p53 turnover
in which we assume that p53 binds to the E3 ligase Mdm2
and is then ubiquitinated and targeted for degradation by
the 26S proteasome. Under normal (unstressed) conditions,
both p53 and Mdm2 are kept at low basal levels. However,
when cells are stressed and DNA damage occurs, p53 is
phosphorylated and is then unable to bind to Mdm2 and
so is no longer degraded. Therefore p53 levels increase. In
addition, phosphorylation of p53 increases its activity. Full
details of this module are already published [16]. Under
normal conditions when p53 levels are low, it is unable to
bind to GSK3β and so we assume that GSK3β activity is low
when cells are not stressed.
The model also includes reactions for the production,
clearance and aggregation of Aβ, and the phosphoryla-
tion/dephosphorylation and aggregation of tau. In addition
we assume that Aβ results in increased generation of ROS
and increased transcription of p53. The full details of
the model are available in an open access journal and
the SBML code is available from Biomodels (BioModels
ID:BIOMD0000000286)[18]. The simulations were carried
out using the Gillespie algorithm on the Biology of Ageing
e-Science Integration and Simulation (BASIS) system [19–
21]. The model results were analysed and plotted using the R
package.
3. Results
3.1. Increased Aβ Clearance from Day 0. In our previous
model we set the rates for aggregation of tau and Aβ at levels
so that if there was an increase in tau phosphorylation or
an increase in Aβ production, the formation of aggregates
would appear within 2 or 3 days. In reality, the aggregation
processislikelytohavemuchlongerlagperiods.A cceleration
of the aggregation process in our computer model is merely
a device to increase the throughput of simulations. With
normal rates of Aβ clearance, our model predicts that a small
percentage of cells do not accumulate any plaques or tangles
by 12 days (Figures 2(c) and 2(f)). However, the majorityInternational Journal of Alzheimer’s Disease 3
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Figure 2: Simulation output for model with high aggregation rates and normal Aβ clearance. Three diﬀerent individual simulations are
shown.Theplotsineachcolumnarefromthesamesimulation.(a)–(c)Levelsofp53(totalpoolincludingboundandubiquitinatedspecies).
(e,f) p53 bound to GSK3β (GSK3b p53), damaged DNA (damDNA), tau tangles, and Aβ plaques are shown.
of simulated cells accumulate both plaques and tangles due
to stochastic DNA damage which leads to increased levels
and activation of p53 (Figures 2(a), 2(b), 2(d) and 2(e)). The
modelpredictsthatasaresultofp53activation,GSK3βactiv-
ity increases resulting in increased phosphorylation of tau
and formation of tau tangles. In addition, increased p53 and
GSK3β activity result in increased production of Aβ which
then aggregates to form plaques. Interestingly, the model
predicts that tau tangles precede Aβ plaques suggesting that
plaques and tangles are formed independently. The increase
in Aβ also leads to more ROS and further DNA damage
which in turn leads to further activation of p53 and a cycle
ensues. Increasing the clearance rate of Aβ, by two orders of
magnitude, at day 0 prevents any accumulation of plaques
or tangles and p53 levels remain low over a simulated 12-day
period(Figure 3,gr eencurv eandFigure 4(a)).Thissupports
the hypothesis that the increase in ROS via Aβ reinforces the
cycle by activation of p53 and GSK3β as suggested above.
3.2. Eﬀect of Increasing Aβ Clearance at Diﬀerent Time
Points. It is of interest to examine the eﬀect of increasing
Aβ clearance at later timepoints, since such interventions
may occur after soluble Aβ or even plaques have had time
to form. Studies on Aβ immunization in mice indicate
that interventions are more eﬀective if administered early,
suggesting that the load of Aβ at the time of immunization
is important [22]. We therefore used the model to explore
the eﬀect of increasing the clearance of Aβ at diﬀerent4 International Journal of Alzheimer’s Disease
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Figure 3: Levels of p53 under conditions of high aggregation rates
and increased Aβ clearance at diﬀerent time points. Each line
shows the mean levels of p53 (total pool including bound and
ubiquitinated species) from 100 simulations over a 12-day period.
time points (Figures 3 and 4). This was done by adding a
timed event to the SBML code so that the parameter for Aβ
clearance is reduced by two orders of magnitude at time 2,
4, 6, or 8 days from the start of the simulation. The model
predicts that increasing Aβ clearance at early time points (up
to day 4) leads to a much lower level of Aβ so that no plaques
form and there are also much lower levels of tau tangles and
p53 (Figures 3, 4(a)–4(c)). Note that the intervention at day
2l e a d st ol o wl e v e l so fA β monomers which are suﬃcient
to slightly increase ROS levels (black curve in Figure 4(b)).
Accordingly p53 levels rise slightly (red line in Figure 3)a n d
the activity of GSK3β is increased leading to an increase in
phosphorylation and aggregation of tau (Figure 4(b)). Inter-
ventions at later time points (day 6 or later) result in lower
levels of plaques compared to normal Aβ clearance (compare
light blue curves in Figures 4(d) and 4(e) with 4(f)) but the
levels of tau tangles are not signiﬁcantly lower compared to
no intervention (Figures 4(d)–4(f), dark blue curves). This
is due to the formation of Aβ monomers and oligomers
occurring before the intervention, which leads to increases
in ROS, activation of GSK3β, and increased phosphorylation
of tau which is then more likely to form tangles. Figure 3
shows p53 levels start to increase after day 2 and continue
to increase until the intervention of increased Aβ clearance
occurs. This can be seen clearly by the fact that all curves
are initially close together but as the intervention occurs, p53
levels stabilise. The model therefore suggests that even a low
level of soluble Aβ monomers and oligomers is suﬃcient to
trigger an increase in ROS, which leads to an increase in p53.
3.3.InhibitionofROSProductionviaAβ. Toconﬁrmwhether
the increase in p53 is due to Aβ-mediated ROS production,
we ran 100 simulations in the model with increased Aβ
clearance at day 8 and blocked the production of ROS
via Aβ (by setting the parameter for Aβ-mediated ROS
production to zero). Figure 5(a) shows the mean value of
these simulations for p53, GSK3β bound to p53, Aβ plaques,
tau tangles, and damaged DNA over a 12-day period. It can
be seen that with the exception of p53, the levels of the all
species shown are close to zero. So the model predicts that
this intervention completely prevents the increase in DNA
damage, the elevation of p53, the increase in GSK3β activity,
and the formation of plaques and tangles producing results
similartoincreasedclearanceofAβ atday0(seeFigure 4(a)).
3.4. Inhibition of GSK3β/p53 Binding. To examine the eﬀect
of GSK3β/p53 binding on the aggregation process we
inhibited the interaction between GSK3β and p53 (by setting
the parameter for GSK3β/p53 binding to zero). We ran 100
simulations with increased clearance of Aβ on day 8 (with
ROS production via Aβ restored). This additional interven-
tionalsopreventedtheformationofplaquesandtangleseven
though p53 levels rose during the simulation (Figure 5(b)).
Therefore the model predicts that Aβ c l e a r a n c ea tl a t et i m e
points may be beneﬁcial if additional interventions are used
suchassimultaneouslyreducingROSlevelsorpreventingthe
activation of GSK3β.
3.5. Eﬀect of Aβ Immunization on Neuronal Loss. Cell death
is not currently explicitly included in the model, but we can
assume that if p53 reaches a threshold then it triggers an
apoptotic pathway. Since it would be unrealistic to assign to
the threshold an exact and invariable value, the threshold
level of p53 is chosen from a random distribution (normal
distribution,mean600,variance50)foreachsimulationrun.
For each simulation the level of p53 was tracked over time,
starting at time zero. If the level of p53 exceeded the chosen
threshold, the time at which this occurred was recorded and
the simulated cell was considered to have undergone cell
d e a t ha tt h i st i m e .T h ep e r c e n t a g eo fv i a b l ec e l l sa te a c ht i m e
point was calculated for each of the intervention times and
plotted (Figure 6). The model predicts that there are no cell
deaths if Aβ clearance is increased at early time points but
as the intervention is increasingly delayed the percentage of
cell death increases. If the intervention is as late as day 8,
there is little improvement in cell viability compared to no
intervention. The model therefore indicates that increased
clearance of Aβ needs to occur at early time points before
there is any accumulation of Aβ.
4. Discussion
The model shows that reducing the burden of Aβ reduces
levels of ROS, which leads to less DNA damage, lower p53
activity, lower GSK3β activity, and reduced tau phosphory-
lation. If Aβ clearance is increased at early time points, there
is a decrease in plaques and also a reduction in tau tangles.
The model therefore does not support a dual pathway
(Figure 1(b)). On the other hand, increasing Aβ clearance at
latetimepointsreducedplaqueformationbutdidnotreduceInternational Journal of Alzheimer’s Disease 5
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Figure 4: Simulation results for model with high aggregation rates and increased Aβ clearance at diﬀerent time points. Each graph shows the
mean of 100 simulations. The clearance rate of Aβ was increased at the following time points: (a) Day 0, (b) Day 2, (c) Day 4, (d) Day 6, (e)
Day 8, (f) No intervention. p53 bound to GSK3β (GSK3b p53), damaged DNA (damDNA), ROS, tau tangles and Aβ monomers, oligomers
and plaques, are shown.
tangle formation. Neither then does the model support a
linear pathway (Figure 1(a)). Rather the model supports
the complex pathway where plaques and tangles can form
independently due to an upstream event but with increased
tangle formation in the presence of Aβ (Figure 1(c)). We
propose a new hypothesis in which the pathway between Aβ
and tau is via ROS, p53, and GSK3β (Figure 7). It is impor-
tant to note that GSK3β, which is shown at the top of the
diagram, is not necessarily the starting point for the ensuing
cascade of events. For example, the initiating event could6 International Journal of Alzheimer’s Disease
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Figure 7: New hypotheses of AD involving GSK3 and p53. Our model supports that the pathway between Aβ and tau is via ROS, p53, and
GSK3β. Note that there is a cycle in the diagram between GSK3β,A β, ROS, and p53 which can start at any point. Full details are in the text.
be an increase in soluble Aβ which then leads to plaques
and an increase in ROS. Elevated ROS may then cause DNA
damage which results in increased levels of p53, followed by
increased activity of GSK3β. Finally the increased activity
of GSK3β leads to tau hyperphosphorylation and tangle
formation.Inaddition,levelsofAβareincreasedandsothere
is a positive feedback loop which reinforces the cycle on the
left. Note that GSK3β also increases p53 activity providing
an additional positive feedback in the cycle. The cycle could
also begin with increased ROS due to cellular stress, an
increase in dysfunctional mitochondria, and/or a decline in
the eﬃciency of the antioxidant system. Furthermore, the
cycle could begin with p53 due to stress-induced DNA dam-
age, telomere uncapping, or inhibition of the proteasome.
Whatever the initiating event the positive feedback loops
could promote a self-perpetuating and amplifying cascade of
events that could lead to frank AD.
The model also supports the amyloid hypothesis for
familial forms of the disease, since the initiating event for
this form of the disease would be increased production of
Aβ due to mutations in genes involved in APP processing. In
this case the cycle starts with Aβ and then leads to increased
ROS, DNA damage, increased levels of p53, increased
GSK3β activity, and ﬁnally hyperphosphorylation of tau and
formation of tangles in a seemingly linear pathway. The
model also explains why tau pathology may be seen before
plaques or even without plaques if the initiating event is
increased activity of GSK3β, or if the cycle starts with ROS
or p53. The scenario in which tangles appear without any
plaques would suggest however that there must also be more
eﬃcient clearance of Aβ since an increase in GSK3β activity
also increases Aβ production.
There is experimental data to support all the arrows in
the diagram, however the importance of p53 in the loop
has not been fully investigated. Although it is known that
p53 increases the activity of GSK3β [23] and that increased
p53 activity indirectly leads to tau hyperphosphorylation
[24], as yet no experiments have been carried out to prove
that the link between p53 and tau is GSK3β as our model
suggests. This prediction could be tested experimentally by
either inhibiting or overexpressing p53 in cells expressing Aβ
and then measuring GSK3β activity and levels of phospho-
tau.
The model is a simpliﬁcation of the system but as the
model is encoded in SBML, it can easily be extended to
include further details. Other important components which
could be added are chaperones (GSK3β is a client of Hsp90),
more detail of tau regulation, the insulin pathway, and wnt
signalling pathways. It would be of particular interest to
include the insulin signalling pathway in order to explore the
connection between ADand type 2 diabetes since GSK3β has
been implicated in both diseases. Mitochondria also play an
important role in the disease process. For example, damaged
mitochondria may accumulate in postmitotic neurons and
cause an increase in ROS which could start the vicious
cycle shown in Figure 7. In addition, soluble Aβ binds to
Aβ-binding alcohol dehydrogenase (ABAD) which leads to
increase ROS via mitochondrial dysfunction [25, 26]. Recent
data show that truncated tau and Aβ act cooperatively to
impair mitochondrial function and reduce mitochondrial
transport in neurons [27]. A model of mitochondrial
dynamics is currently being developed and linking this with
the current model will give a more complete picture of the
disease process.8 International Journal of Alzheimer’s Disease
Aβ immunotherapy works by either active immuniza-
tion with Aβ aggregates or by passive transfer of anti-
Aβ antibodies. Both approaches have been shown to pre-
vent Aβ deposition and to clear already existing plaques.
Wilcock et al. showed two phases in the clearance of
plaques [28]. First, there was a sharp decline in plaques 24
hours after immunization due to disaggregation and then
a further decline about 3 days later due to the activation
of microglia which removed the plaques by phagocytosis
[28]. Our current model could be modiﬁed to mimic the
immunization process by including additional reactions for
plaque disaggregation and clearance. The disaggregation of
plaques leads to an increase in soluble Aβ and since these
may be toxic due to their interaction with mitochondria
and their involvement in ROS production, our model may
show that such an intervention would be less beneﬁcial
than the increased clearance of soluble Aβ. Therefore, the
model could prove very useful for testing the consequences
of diﬀerent interventions.
5. Conclusions
Our mathematical model supports a complex pathway
linking Aβ and tau via GSK3β, p53, and oxidative stress.
Importantly, the pathway contains a cycle with multiple
points of entry. It is this property of the pathway which
enables the model to be consistent with both the amyloid
hypothesis for familial AD and a more complex pathway for
sporadic forms.
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